CHICAGO (Reuters) - Drugmakers are working on experimental diabetes drugs using a novel mechanism to help flush excess blood sugar out of the body, according to results of small studies presented at a medical meeting on Sunday.Bristol-Myers Squibb hopes their drug, known as dapagliflozin, will be the first in a new class that seeks to block the reabsorption of glucose to lower elevated blood sugar levels in diabetics. GlaxoSmithKline Plc is also working on a drug using the same concept.
